In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.
We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.
Key topics covered in this episode:
Frontline treatment options for DLBCL
The role of polatuzumab in early-stage disease
Treatment paradigms for advanced-stage DLBCL
CAR T-cell therapy: who should receive it and when
The importance of community and tertiary care partnerships in improving patient access to innovative therapies
Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
